Skip to main content
Top
Published in:

01-04-2023 | Testosterone | Original Article

The association of serum testosterone with dyslipidemia is mediated by obesity: the Henan Rural Cohort Study

Authors: C. Fan, D. Wei, L. Wang, P. Liu, K. Fan, L. Nie, X. Liu, J. Hou, W. Huo, L. Li, X. Li, W. Li, C. Wang, Z. Mao

Published in: Journal of Endocrinological Investigation | Issue 4/2023

Login to get access

Abstract

Background and aims

This study aimed to evaluate the relationships of serum testosterone with dyslipidemia and blood lipid levels and test whether obesity mediated these associations by gender in Chinese rural population.

Methods and results

A total of 6150 subjects were finally analyzed in this study. Serum testosterone for each subject was detected by liquid chromatography equipped with tandem mass spectrometry. Logistic regression and linear regression were employed to evaluate the associations of serum testosterone with the prevalence of dyslipidemia and blood lipid levels. Mediation analysis was conducted to identify the mediation effects of obesity on the relationship between serum testosterone and dyslipidemia. After adjusting for multiple confounders, per unit change in serum ln-testosterone levels was associated with a decreased prevalent dyslipidemia in men (odds ratio (OR): 0.785, 95% confidence interval (CI) (0.708, 0.871)). Males with the levels of serum testosterone in the third or fourth quartiles had a 49.4% (OR: 0.506, 95% CI 0.398, 0.644) or 67.1% (OR: 0.329, 95% CI 0.253, 0.428) significantly lower odds of prevalence of dyslipidemia. In addition, a onefold increase in ln-testosterone was related to a 0.043 mmol/L (95% CI 0.028, 0.059) increase in high-density lipoprotein cholesterol (HDL-C) in men. Results of the mediation analysis suggested that obesity played a partial role in the association of testosterone with dyslipidemia in men.

Conclusions

These findings suggested that serum testosterone levels were negatively associated with lipid levels and prevalent dyslipidemia, and obesity mediated the effects of serum testosterone on dyslipidemia in men, implying that obesity prevention should be highlighted to decrease the prevalence of dyslipidemia related to changes in testosterone levels.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mendis S, Davis S, Norrving B (2015) Organizational update: the world health organization global status report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease. Stroke 46(5):e121–e122CrossRefPubMed Mendis S, Davis S, Norrving B (2015) Organizational update: the world health organization global status report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease. Stroke 46(5):e121–e122CrossRefPubMed
2.
go back to reference Yusuf S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438):937–952CrossRefPubMed Yusuf S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438):937–952CrossRefPubMed
3.
go back to reference Pan L et al (2016) The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis 248:2–9CrossRefPubMed Pan L et al (2016) The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis 248:2–9CrossRefPubMed
4.
go back to reference Opoku S et al (2019) Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China national stroke screening and prevention project (CNSSPP). BMC Public Health 19(1):1500CrossRefPubMedPubMedCentral Opoku S et al (2019) Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China national stroke screening and prevention project (CNSSPP). BMC Public Health 19(1):1500CrossRefPubMedPubMedCentral
5.
go back to reference Liu X et al (2018) Dyslipidemia prevalence, awareness, treatment, control, and risk factors in Chinese rural population: the Henan rural cohort study. Lipids Health Dis 17(1):119CrossRefPubMedPubMedCentral Liu X et al (2018) Dyslipidemia prevalence, awareness, treatment, control, and risk factors in Chinese rural population: the Henan rural cohort study. Lipids Health Dis 17(1):119CrossRefPubMedPubMedCentral
7.
go back to reference Corona G et al (2014) Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med 11(6):1577–1592CrossRefPubMed Corona G et al (2014) Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med 11(6):1577–1592CrossRefPubMed
8.
go back to reference Haring R et al (2011) Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia. Eur J Cardiovasc Prev Rehabil 18(1):86–96CrossRefPubMed Haring R et al (2011) Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia. Eur J Cardiovasc Prev Rehabil 18(1):86–96CrossRefPubMed
9.
go back to reference Cardarelli R et al (2014) The association of free testosterone levels in men and lifestyle factors and chronic disease status: a north texas healthy heart study. J Prim Care Community Health 5(3):173–179CrossRefPubMed Cardarelli R et al (2014) The association of free testosterone levels in men and lifestyle factors and chronic disease status: a north texas healthy heart study. J Prim Care Community Health 5(3):173–179CrossRefPubMed
10.
go back to reference Makinen JI et al (2008) Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis 197(2):688–693CrossRefPubMed Makinen JI et al (2008) Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis 197(2):688–693CrossRefPubMed
11.
go back to reference Akishita M et al (2010) Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men. Hypertens Res 33(6):587–591CrossRefPubMed Akishita M et al (2010) Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men. Hypertens Res 33(6):587–591CrossRefPubMed
12.
go back to reference Agledahl I et al (2008) Low serum testosterone in men is inversely associated with non-fasting serum triglycerides: the Tromsø study. Nutr Metab Cardiovasc Dis 18(4):256–262CrossRefPubMed Agledahl I et al (2008) Low serum testosterone in men is inversely associated with non-fasting serum triglycerides: the Tromsø study. Nutr Metab Cardiovasc Dis 18(4):256–262CrossRefPubMed
13.
go back to reference Zhang N et al (2014) The relationship between endogenous testosterone and lipid profile in middle-aged and elderly Chinese men. Eur J Endocrinol 170(4):487–494CrossRefPubMed Zhang N et al (2014) The relationship between endogenous testosterone and lipid profile in middle-aged and elderly Chinese men. Eur J Endocrinol 170(4):487–494CrossRefPubMed
14.
go back to reference Lambrinoudaki I et al (2006) Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. Eur J Endocrinol 154(6):907–916CrossRefPubMed Lambrinoudaki I et al (2006) Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. Eur J Endocrinol 154(6):907–916CrossRefPubMed
15.
go back to reference Phillips GB et al (2000) Association of hyperandrogenemia and hyperestrogenemia with type 2 diabetes in Hispanic postmenopausal women. Diabetes Care 23(1):74–79CrossRefPubMed Phillips GB et al (2000) Association of hyperandrogenemia and hyperestrogenemia with type 2 diabetes in Hispanic postmenopausal women. Diabetes Care 23(1):74–79CrossRefPubMed
16.
go back to reference Bays HE et al (2013) Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol 7(4):304–383CrossRefPubMed Bays HE et al (2013) Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol 7(4):304–383CrossRefPubMed
19.
go back to reference Tsai EC et al (2000) Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord 24(4):485–491CrossRefPubMed Tsai EC et al (2000) Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord 24(4):485–491CrossRefPubMed
20.
go back to reference Khaw KT, Barrett-Connor E (1992) Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 2(5):675–682CrossRefPubMed Khaw KT, Barrett-Connor E (1992) Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 2(5):675–682CrossRefPubMed
22.
go back to reference Wei D et al (2021) Interaction between testosterone and obesity on hypertension: a population-based cross-sectional study. Atherosclerosis 330:14–21CrossRefPubMed Wei D et al (2021) Interaction between testosterone and obesity on hypertension: a population-based cross-sectional study. Atherosclerosis 330:14–21CrossRefPubMed
23.
go back to reference Diagnosis and classification of diabetes mellitus (2009) Diabetes Care, 32 (Suppl 1) S62–7 Diagnosis and classification of diabetes mellitus (2009) Diabetes Care, 32 (Suppl 1) S62–7
24.
go back to reference Canguven O et al (2017) Testosterone therapy has positive effects on anthropometric measures, metabolic syndrome components (obesity, lipid profile, diabetes mellitus control), blood indices, liver enzymes, and prostate health indicators in elderly hypogonadal men. Andrologia 49(10):e12768CrossRef Canguven O et al (2017) Testosterone therapy has positive effects on anthropometric measures, metabolic syndrome components (obesity, lipid profile, diabetes mellitus control), blood indices, liver enzymes, and prostate health indicators in elderly hypogonadal men. Andrologia 49(10):e12768CrossRef
25.
go back to reference Corona G et al (2011) Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 8(1):272–283CrossRefPubMed Corona G et al (2011) Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 8(1):272–283CrossRefPubMed
26.
go back to reference Maseroli E et al (2021) Testosterone treatment is associated with reduced adipose tissue dysfunction and nonalcoholic fatty liver disease in obese hypogonadal men. J Endocrinol Invest 44(4):819–842CrossRefPubMed Maseroli E et al (2021) Testosterone treatment is associated with reduced adipose tissue dysfunction and nonalcoholic fatty liver disease in obese hypogonadal men. J Endocrinol Invest 44(4):819–842CrossRefPubMed
27.
go back to reference Solomon H et al (2006) Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract 60(2):141–145CrossRefPubMed Solomon H et al (2006) Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract 60(2):141–145CrossRefPubMed
28.
go back to reference Coogan PF, Rosenberg L, Strom BL (2007) Statin use and the risk of 10 cancers. Epidemiology 18(2):213–219CrossRefPubMed Coogan PF, Rosenberg L, Strom BL (2007) Statin use and the risk of 10 cancers. Epidemiology 18(2):213–219CrossRefPubMed
29.
go back to reference Britto R et al (2012) Improvement of the lipid profile in post menopausal women who use estradiol and testosterone implants. Gynecol Endocrinol 28(10):767–769CrossRefPubMed Britto R et al (2012) Improvement of the lipid profile in post menopausal women who use estradiol and testosterone implants. Gynecol Endocrinol 28(10):767–769CrossRefPubMed
30.
go back to reference Wang X, Magkos F, Mittendorfer B (2011) Sex differences in lipid and lipoprotein metabolism: it’s not just about sex hormones. J Clin Endocrinol Metab 96(4):885–893CrossRefPubMedPubMedCentral Wang X, Magkos F, Mittendorfer B (2011) Sex differences in lipid and lipoprotein metabolism: it’s not just about sex hormones. J Clin Endocrinol Metab 96(4):885–893CrossRefPubMedPubMedCentral
31.
go back to reference Hewitt KN et al (2003) The aromatase knockout mouse presents with a sexually dimorphic disruption to cholesterol homeostasis. Endocrinology 144(9):3895–3903CrossRefPubMed Hewitt KN et al (2003) The aromatase knockout mouse presents with a sexually dimorphic disruption to cholesterol homeostasis. Endocrinology 144(9):3895–3903CrossRefPubMed
32.
go back to reference Clark RV et al (2019) Large divergence in testosterone concentrations between men and women: frame of reference for elite athletes in sex-specific competition in sports, a narrative review. Clin Endocrinol (Oxf) 90(1):15–22CrossRefPubMed Clark RV et al (2019) Large divergence in testosterone concentrations between men and women: frame of reference for elite athletes in sex-specific competition in sports, a narrative review. Clin Endocrinol (Oxf) 90(1):15–22CrossRefPubMed
33.
go back to reference Pizzocaro A et al (2020) Testosterone treatment in male patients with Klinefelter syndrome: a systematic review and meta-analysis. J Endocrinol Invest 43(12):1675–1687CrossRefPubMed Pizzocaro A et al (2020) Testosterone treatment in male patients with Klinefelter syndrome: a systematic review and meta-analysis. J Endocrinol Invest 43(12):1675–1687CrossRefPubMed
34.
go back to reference Langer C et al (2002) Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun 296(5):1051–1057CrossRefPubMed Langer C et al (2002) Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun 296(5):1051–1057CrossRefPubMed
35.
go back to reference Tsai EC et al (2004) Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care 27(4):861–868CrossRefPubMed Tsai EC et al (2004) Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care 27(4):861–868CrossRefPubMed
36.
go back to reference Liu X et al (2019) Association of serum testosterone with different classes of glucose metabolism and the mediation effect of obesity: the henan rural cohort study. Diabetes Metab Res Rev 35(5):e3133CrossRefPubMed Liu X et al (2019) Association of serum testosterone with different classes of glucose metabolism and the mediation effect of obesity: the henan rural cohort study. Diabetes Metab Res Rev 35(5):e3133CrossRefPubMed
37.
go back to reference Rovira-Llopis S et al (2017) Low testosterone levels are related to oxidative stress, mitochondrial dysfunction and altered subclinical atherosclerotic markers in type 2 diabetic male patients. Free Radic Biol Med 108:155–162CrossRefPubMed Rovira-Llopis S et al (2017) Low testosterone levels are related to oxidative stress, mitochondrial dysfunction and altered subclinical atherosclerotic markers in type 2 diabetic male patients. Free Radic Biol Med 108:155–162CrossRefPubMed
38.
go back to reference Allan CA et al (2008) Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 93(1):139–146CrossRefPubMed Allan CA et al (2008) Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 93(1):139–146CrossRefPubMed
Metadata
Title
The association of serum testosterone with dyslipidemia is mediated by obesity: the Henan Rural Cohort Study
Authors
C. Fan
D. Wei
L. Wang
P. Liu
K. Fan
L. Nie
X. Liu
J. Hou
W. Huo
L. Li
X. Li
W. Li
C. Wang
Z. Mao
Publication date
01-04-2023
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 4/2023
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-022-01911-6

Other articles of this Issue 4/2023

Journal of Endocrinological Investigation 4/2023 Go to the issue

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more